Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of Valvate Kiwifruit glycoside E and Valvate Kiwifruit glycoside F in preparation of medicaments for resisting myocardial ischemia

A kind of anti-myocardial ischemia technology of kiwifruit, which is applied in drug combination, cardiovascular system diseases, pharmaceutical formulations, etc., can solve problems such as adverse effects and waste that cannot be effectively and timely removed

Active Publication Date: 2013-02-06
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, metabolic waste cannot be removed effectively and in a timely manner, which is prone to adverse effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Valvate Kiwifruit glycoside E and Valvate Kiwifruit glycoside F in preparation of medicaments for resisting myocardial ischemia
  • Application of Valvate Kiwifruit glycoside E and Valvate Kiwifruit glycoside F in preparation of medicaments for resisting myocardial ischemia
  • Application of Valvate Kiwifruit glycoside E and Valvate Kiwifruit glycoside F in preparation of medicaments for resisting myocardial ischemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Embodiment 1 (preparation of p-actinin E, F tablet)

[0100] Take 200g of Actinidinin E and F, 50g of hydroxypropyl methylcellulose, 100g of microcrystalline cellulose, and 20g of croscarmellose sodium, mix well, add an appropriate amount of 60% ethanol to make a soft material, pass Granulate with a 24-mesh sieve, dry at 50°C for 2 hours, pass the dried granules through a 30-mesh sieve for granulation, add 2.5g of magnesium stearate, mix well, and press into 2000 tablets, that is, actiniferin E and F tablets respectively.

Embodiment 2

[0101] Embodiment 2 (preparation of p-actinin E, F capsules)

[0102] Take 40g of actinin E and F respectively, add 40%~60% starch, dextrin, carboxymethyl starch, calcium hydrogen phosphate and other fillers, 0.5%~10% disintegrant sodium carboxymethylcellulose, hydroxyl Propyl cellulose is made into granules and dried, and glidant magnesium stearate and micropowdered silica gel are added to dry them, and packed into capsules to obtain Actinidin E and F capsules respectively.

Embodiment 3

[0103] Embodiment 3 (preparation of p-actinin E, F injection)

[0104] Take appropriate amounts of Actinidin E and F respectively, add purified water for injection and appropriate amounts of polysorbate 80, and make injections containing 100 mg of Actinidin E and F per 25 ml for intravenous or injection use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel medicinal application of flavonoid gylcosides, such as Valvate Kiwifruit glycoside E, Valvate Kiwifruit glycoside F, and mixture of the Valvate Kiwifruit glycoside E and the Valvate Kiwifruit glycoside F, in particular application of the Valvate Kiwifruit glycoside E, Valvate Kiwifruit glycoside F or the mixture of the Valvate Kiwifruit glycoside E and the Valvate Kiwifruit glycoside F to preparation of medicaments for resisting myocardial ischemia. In the embodiment of the invention, pharmacologic researches show that the Valvate Kiwifruit glycoside E and the Valvate Kiwifruit glycoside F have accurate effects of resisting the myocardial ischemia; and the previous researches show that the Valvate Kiwifruit glycoside E and the Valvate Kiwifruit glycoside F have high security, obvious advantages and wide development and utilization prospect, and are low in price, and convenient to prepare.

Description

technical field [0001] The present invention relates to a new medical application of actactin E, actactin F, or a mixture of the two. Background technique [0002] Myocardial ischemia refers to a clinical state in which coronary blood flow decreases due to various reasons, resulting in insufficient supply of myocardial oxygen and other substances and reduced clearance of metabolites. Clinically, the main and most common cause of myocardial ischemia is coronary artery (occasionally pulmonary artery) stenosis, and the main cause of coronary artery stenosis is atherosclerosis, and heart disease caused by coronary atherosclerosis is coronary artery disease. Heart disease, so it can be said that coronary heart disease is the "culprit" of myocardial ischemia. Myocardial ischemia may have many adverse effects on the heart and the whole body. Oxygen is an essential substance for the activity of cardiomyocytes, and oxygen is transported to the cells through the blood. The direct c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P9/10
Inventor 辛海量凌昌全曲丽萍苏永华李同明
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY